Non-financial reporting

We create value for all our stakeholders and track our performance against key financial and non-financial indicators. These indicators are grouped under our main areas of engagement:

Key performance indicators (KPIs)

 

Innovating for patients

Our primary contribution to healthcare is to invent and develop medicines and diagnostics that significantly improve people’s lives. This entails a commitment to working with many different partners to continuously and sustainably reduce the barriers that prevent or impede access to our products.

Providing a great workplace

We aim to provide a work environment where our employees are encouraged to build their careers and pursue their passions. By providing everyone with the opportunity for career development, we ensure the growth of our single largest investment – our employees – and, in turn, the success of our organisation.

Being a trustworthy partner

Open and constructive dialogue with our stakeholders is crucial to creatingsustainable value and growth. It helps us to better understand how to serve patients, their carers nd physicians, and to focus our activities on creating value for both the company and society.

Protecting the environment

Roche has been committed to mitigating environmental impact and climate change for many years, proactively seeking new, more sustainable technologies and processes to achieve this goal.

Delivering continued growth

We aim to continuously create value for our stakeholders and to achieve sustainable, high profitability. We do this in order to maintain our commitment to research, to ensure our growth and independence, to provide employment opportunities, to cover risks, and to pay an attractive return on invested capital.

The marked figures (✓PwC) were reviewed by the PricewaterhouseCoopers auditing firm.

 

(1) The patient number estimates how many treatments for specific diseases have been delivered in one year. It is based on the medicines sold and adjusted by average daily dose, treatment duration and compliance.

(2) Patients included in interventional trials. Interventional trials refer to all Roche sponsored/funded and supported (eg. IIS, collaborative group, partner) studies incl phase 1-3, phase 4, where patients have been enrolled.

(3) Based on the World Bank Country classifications, July 1st 2014

(4) Medicines launched in the US

(5) Top positions at corporate and operating Group level

(6) GEOS is not done on a yearly basis. Last surveys were conducted in 2017 and 2014.

(7) Partnerships also include license agreements, research and technology collaborations as well as clinical trial collaborations

(8) Audit Target: This refers to approximately 1 000 business critical suppliers, where we see the highest risk exposure and a five-year audit cycle. For our Diagnostics Division this also includes quality audits.

(9) PSCI audit reports or filled-in PSCI questionnaires

(10) Preferred Suppliers include critical, strategic and leverage suppliers, plus suppliers that are in scope of Supplier Diversity programs. 2015 figures: direct spend only.

(11) The Roche eco-balance refers to the consumption of energy and resources and the pollution caused by business activities. It thus describes the total environmental impact of our operations

(12) Core results exclude non-core items such as global restructuring charges and amortisation and impairment of goodwill and intangible assets

(13) For the year 2017 as proposed by the Board of Directors